Postmarketing withdrawal of human medicinal products because of adverse reactions in animals: a systematic review and analysis.
Igho J OnakpoyaCarl J HeneghanJeffrey K AronsonPublished in: Pharmacoepidemiology and drug safety (2017)
Regulatory authorities and drug manufacturers are likely to withdraw medicinal products quickly from the market when animal experiments suggest increased risks of cancers or congenital malformations. Human studies are seldom conducted when harms are suspected in animals. Future research should explore better methods of extrapolating harms data from animal research to humans.